Alzheimer disease (AD) is the most common form of dementia, aff ecting 5.5 million people in the US. Progressive neurodegeneration results in relentless cognitive decline, posing a substantial public health burden, and has major implications at the individual level. AD phenotypes are divided into early-onset (EOAD) and late-onset (LOAD) AD with the arbitrary cutoff of 65 years in most studies [1] .
preserved in EOAD compared with LOAD [9] . Th e literature suggested that language is more aff ected in EOAD with preservation of visuospatial function [10, 11] , whereas more recently, praxis and visuospatial function appeared to be more aff ected when compared with LOAD [12] . Most research data support the hypothesis that there is greater involvement of the frontal-parietal structures in EOAD and more predominant defi cits in temporal lobe function with a propensity for the left hemisphere in LOAD [11, 13, 14] .
Studies investigating the rate of disease progression by measuring cognitive and functional abilities over time yielded variable results. Some reports demonstrated that EOAD shows a more rapid progression [15] [16] [17] , and others found that AOO is not a major predictor of the rate of progression [18, 19] .
Most voxel-based volumetric magnetic resonance imag ing studies found that, in LOAD, hippocampal atrophy is prominent [20] whereas the pattern in EOAD is more variable. In EOAD, instances of atrophy of the temporal-parietal [21] , parietal-occipital [20] , temporal and posterior cingulate [22] , and precuneus [23] areas have been reported. Th e variability is likely due to study design, especially the selection of controls. Although there is some agreement that EOAD initially aff ects mainly the parietal associative cortex and LOAD aff ects the hippocampus, there are signifi cant variability and overlap between the two groups.
Evidence from brain metabolism studies suggests that EOAD is associated with changes that are more extensive, and studies most commonly report involvement of the precuneus and occipital cortex [24] [25] [26] , and one study reports extension to the frontal cortex and subcortical grey matter [26] . Recent data indicate that regional or global [ 11 C]-labelled Pittsburgh com pound B binding is similar in early-onset and late-onset patients. In contrast, early-onset patients exhibit glucose metabolism that is signifi cantly lower than that of late-onset patients in precuneus/posterior cingulate, lateral temporo-parietal, and occipital corticies [27] . Th e auto somal dominant subset of EOAD demonstrates early uptake of Pittsburgh compound B in the caudate and the putamen [28, 29] . Amyloid positron emission tomography studies using cerebellar uptake as reference may be confounded because of increased cerebellar uptake in the autosomal dominant subset.
Studies comparing biomarkers in the cerebrospinal fl uid in EOAD and LOAD demonstrated that betaamyloid level is signifi cantly lower in EOAD as compared with LOAD, with high sensitivity in both groups as a diagnostic marker [30] .
Pathological studies demonstrated that the pathological hallmarks of AD and their regional distribution are similar [31] ; however, quantitatively, a higher number of neuritic plaques and neurofi brillary tangles were found for the same severity of dementia in the EOAD group [32] [33] [34] . Th e autosomal dominant subset of EOAD demon strates gene-and mutation-specifi c diff erences in small case series, although all mutations are associated with the typical AD pathology and fulfi ll the diagnostic criteria of the Consortium to Establish a Registry for Alzheimer's Disease [35, 36] .
Th e above-reviewed literature suggests that EOAD and LOAD are not likely to be fundamentally diff erent, as clinical, imaging, pathological, and biomarker data overlap and various studies have shown variable results; the data rather suggest heterogeneity of AD. Hetero genenity decreases power, and thus one important question is whether including EOAD cases in clinical trials would add to heterogeneity and work against the ability to demonstrate drug-placebo diff erences. Th e greatest accumu lation of data on disease heterogeneity in AD involving large cohorts (thousands of cases) exists in genetic datasets. As AD has high heritability, it is legitimate to look at genetic heterogeneity of AD since tools are available to study this question and multiple well-designed studies have been reported. Th e genomewide association studies were early to point out the genetic heterogeneity of AD, showing that each locus has a low attributable risk manifesting in small odds ratios [37] [38] [39] . In the comparison of EOAD and LOAD, one of the major diff erences is in the genetic heterogeneity between the two groups. In EOAD, the heritability is higher and culprit genes have been identifi ed. Mutations in three genes account for 11% of the genetic causes, and this genetic load is markedly higher than that of the susceptibility genes in LOAD. In LOAD, causative genes have not been identifi ed, and the strongest risk allele is the APOE4 (apolipoprotein E) allele, conferring in the Caucasian population odds ratios of 10 to 14 in homozygotes and around 3 in heterozygotes [40] . Furthermore, incorporating EOAD cases may intro duce subjects with mutations in APP, PSEN1, and PSEN2. As most animal models for AD involve mutations in one or a combination of these genes [41] , preclinical testing is performed on transgenic animals that in fact model the pathomechanism responsible for AD in this subset of patients. Th is group would be the ideal cohort for proofof-principle studies for amyloid targeted therapies, but this is unfortunately precluded by the rarity of mutation carriers. On the other hand, there is no compelling argument in favor of excluding genetic cases, even from trials assessing the effi cacy of therapies with a nonamyloid target.
Clinical trial design is regulated and guidelines for the design of clinical trials for AD were published by the European Medicines Agency (EMEA) [42] and draft guidelines are available in the US and other countries.
Th ese guidelines do not mention early-onset or genetic AD as an exclusion criterion. Th us, from a regulatory point of view, there is no reason not to include these patients. Th e age range for current clinical trials is variable, with age 55, 60, or 65 years often used as the lower limit cutoff for enrollment. As the defi nition of EOAD is onset at less than 65 years of age, EOAD cases are already enrolled into clinical trials. Th e EOAD subset that is currently excluded likely represents less than 1% of all AD cases and includes the majority of the autosomal dominant cases. Th e conundrum is that we use transgenic animal models based on the amyloid hypothesis to test compounds for effi cacy, and subsequently we exclude the patients whose pathomechanism is closest to the model organism, in which it is most likely that the observed eff ect is replicated. Furthermore, if this 1% were to enroll in clinical trials, they would be randomly assigned, like all patients, to drug or placebo and could not substantially alter the outcome of the trial, even if they had a diff erential response to the treatment. Concerns about a diff erential safety profi le in autosomal dominant EOAD have been raised. As the validity of these concerns are uncertain, safety related to genetic status should be managed in trial design by addressing it in the monitoring procedure and subgroup analysis for the EOAD subset.
Finally, careful consideration of the ethical aspects of exclusion of EOAD patients is warranted. Although the fact is not formally stated, clinical trials exclude EOAD subjects in practice without justifi cation through their inclusion and exclusion criteria. Ethical guidelines stress the importance of considering access to outcomes of research [43] and have established the orphan drug category. Th e category for orphan drug applies if a drug is intended for the diagnosis, prevention, or treatment of a life-threatening or chroni cally debilitating condition that aff ects no more than 5 in 10,000 in the European Community and a disease that aff ects fewer than 200,000 individuals in the US (according to the Orphan Drug Act) [44] . Th e EOAD group is estimated to account for 1% to 6% of subjects with AD, and EOAD aff ects 40,000 to 200,000 individuals in the US or 1.2 to 7.4 in 10,000 individuals in the European Community given an estimated AD prevalence of 1 in 68 people. EOAD cases excluded from clinical trials on the basis of the age criterion likely amount to fewer than 200,000 in the US or fewer than 5 in 10,000. Th e EOFAD (early-onset familial Alzheimer disease) sub group prevalence is fewer than 1 in 10,000, clearly fulfi lling the orphan category criteria. A number of industrialized countries have passed specifi c legislation defi ning epidemiological criteria for the designation of orphan status and consequent incentives to counteract the neglect of orphan disease in industrial research [45] . While distribution of resources is a major consideration, many would uphold that society has a moral obligation not to abandon individuals who had the bad luck to be aff ected by a serious but rare condition for which additional treatments are needed. In addition, medical investigators a professional obligation to advance scien tifi c knowledge. AD represents a category in which drug development is active, but the orphan subset is excluded from research when these patients in fact might benefi t the most, especially from disease-modifying or preventive therapy.
Of the four biomedical ethics principles developed by Beauchamp and Childress [46] -autonomy, nonmalefi cence, benefi cence, and justice -the principles of autonomy, benefi cence, and justice are all relevant for the orphan diseases and for the subset of EOAD cases not currently included in trials. First, autonomy of EOAD subjects is compromised if they wish to contribute to research and are excluded from doing so without justifi cation, and this is the current practice. Second, in regard to the principle of justice, EOAD subjects should have access to and the opportunity to participate in research, and a rights-based approach could further support this claim. Even though the rights-based approach is underrepresented in the literature, its importance is implicit. Th ird, Landman and Henley [47] proposed a basic moral commitment to non-abandonment which would clearly apply to these young and genetically affl icted individuals who suff er from AD.
Finally, we would like to compare and contrast two ethical theories that confl ict in the dilemma of what to do about EOAD subjects: the utilitarian approach, which argues that we seek to maximize the overall good (and do trials involving older, non-genetic AD patients as they represent the majority of cases), and the deontological approach, in which there is an obligation to show good will irrespective of outcome (thus include EOAD subjects in clinical trials). Th e utilitarian approach has several weaknesses in this context. To be able to establish that excluding EOAD subjects would maximize overall good, we would need data to support the risks involved when including EOAD cases. Th e risk implies risk for a negative trial and risk to the individual. We need to estimate the risk for a negative trial imposed by enrolling EOAD subjects to establish that we are maximizing overall good. Heterogeneity would decrease power by decreasing signal-to-noise ratio. However, LOAD is already a heterogeneous disorder and overlaps with EOAD in most characteristics, and thus it is less likely that heterogeneity will increase. In addition, the EOAD subjects would be randomly assigned to active and placebo arms, and this further decreases the problem with a systemic eff ect. In certain instances (especially in trials of amyloid-based therapies), including EOAD subjects and inherently the autosomal dominant subset may increase power by demonstrating a larger eff ect in the genotype-specifi c cases as compared with the multifactorial sporadic cases. If this is the case, the utilitarian theory in fact would call for including EOAD subjects. We need data to evaluate the risk and benefi t, and enrolling EOAD subjects would generate that data. If the protocols address safety issues and a priori protocol design includes subgroup analyses, we would gather data without basically any risk.
In contrast, the deontological approach would concur with the basic moral commitment of non-abandonment of these young individuals devastated by AD. If data from trials enrolling EOAD subjects suggest that there is an increased risk to the trial or to the individual (for example, because of more frequent or severe adverse reactions), the exclusion would have justifi cation and further decisions would be more straightforward. We will not know the answer until we test the hypothesis, and exclusion without justifi cation because of lack of data is ethically unacceptable.
Conclusions
Enrolling EOAD patients in clinical trials has more benefi t than risk involved. Its benefi ts include potentially increasing the power to detect a signal of effi cacy, especially for amyloid-based therapies. Th e EOAD population is unlikely to increase heterogeneity, as the clinical phenotypes, imaging, brain metabolism, biomarker, and pathological characteristics overlap, and LOAD is already a heterogeneous group. Enrolling these patients is ethical and generates data that will help estimate risk and benefi t at the level of the clinical trial and the individual. Th ese risk-benefi t estimates will support informed decisions in the future. It is time to stop discriminating against EOAD patients in our joint eff orts to prevent and treat AD.
